LUNG CANCER

Anne Chiang, MD, PhD, discusses the takeaways from her presentation given at the 18th Annual New York Lung Cancers Symposium.

Antibody-based DLL3-targeting agents and antibody-drug conjugates present exciting treatment possibilities in small cell lung cancer, according to a presentation by Charles Rudin, MD, at the 18th Annual New York Lung Cancer Symposium.

The combination of vibostolimab and pembrolizumab plus docetaxel did not significantly improve progression-free survival compared with docetaxel monotherapy in patients with previously treated metastatic non–small cell lung cancer.

The phase 3 KEYLYNK-008 trial investigating pembrolizumab and olaparib in metastatic squamous non–small cell lung cancer will be stopped due to futility.

Thoracic oncologists discuss the EVOKE-02 study investigating sacituzumab govitecan in combination with pembrolizumab in patients with first-line metastatic NSCLC.

Comprehensive insights on clinical trial data that have led to further development of sacituzumab govitecan for patients with non–small cell lung cancer.

Significant findings from a number of trials in the lung cancer space will make their way into case reports.

In the second article of a 2-part series, Martin F. Dietrich, MD, PhD, discusses the results of the phase 1 CHRYSALIS study of amivantamab for patients with EGFR exon 20 insertion-mutated NSCLC.

Experts on non–small cell lung cancer discuss the role of antibody-drug conjugates and review their mechanism of action.

A review of preclinical studies looking at TROP2 expression in patients with non–small cell lung cancer.

Joshua K. Sabari, MD, offers key takeaways on treating patients with EGFR+ non–small cell lung cancer, highlighting the safety profile.

Expert insights on the treatment of patients with non–small cell lung cancer positive for EGFR mutations and what the PAPILLON study seeks to address.

An expert on EGFR+ non–small cell lung cancer discusses factors that influence treatment decisions.

An overview of recent data from the MARIPOSA trial investigating amivantamab plus lazertinib in patients with EGFR-positive advanced lung cancer.

Joshua K. Sabari, MD, reviews clinical trial data from FLAURA2 on osimertinib plus chemotherapy in patients with EGFR-mutated advanced lung cancer.

A medical oncologist provides an overview of treatment options available for patients with EGFR+ non–small cell lung cancer.

Joshua K. Sabari, MD, reviews the patient profile of a 73-year-old patient with EGFR+ non–small cell lung cancer.

A phase 1/2 study of KSQ-001EX will commence at MD Anderson Cancer Center following this investigational new drug approval from the FDA.

During a Targeted Oncology™ Case-Based Roundtable™ event, Devika Das, MD, discussed the role of KRAS inhibitors and the outcome of the KRYSTAL-1 trial in patients with non–small cell lung cancer. This is the first of 2 articles based on this event.

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, provide an overview of TROP2 as a target for patients with non–small cell lung cancer.

Expert perspectives on unmet needs in the NSCLC treatment landscape and the role of antibody-drug conjugates in addressing them.

At the recent European Society for Medical Oncology Congress 2023, a number of trials evaluated antibody-drug conjugates in non–small cell lung cancer.

Carlos Rojas, MD, discusses preliminary findings from a phase 1 trial which of MK-1084 alone and with pembrolizumab in patients with advanced solid tumors and metastatic non–small cell lung cancer.

Thoracic medical oncologists discuss the evolving role of biomarkers in the non–small cell lung cancer treatment landscape.